Kimberlee Drapkin
Directeur/Membre du Conseil chez KINETA, INC.
Fortune : 5 305 $ au 31/05/2024
Profil
Kimberlee Cobleigh Drapkin is currently an Independent Director at Acumen Pharmaceuticals, Inc., a Non-Executive Director at Imugene Ltd., an Independent Director at Kineta, Inc., and a Director at LENZ Therapeutics, Inc. Previously, she served as the President, CEO, CFO, Director & PAO at Graphite Bio, Inc., an Independent Director at Proteostasis Therapeutics, Inc., an Independent Director at Yumanity Therapeutics, Inc., a Director at Yumanity, Inc., and a Principal at Millennium Pharmaceuticals, Inc. She also held the position of Chief Financial Officer at EPIX Pharmaceuticals, Inc. and served as a Principal at PricewaterhouseCoopers LLP.
Additionally, she was the Chief Financial Officer at Predix Pharmaceuticals, Inc., NinePoint Medical, Inc., Predix Pharmaceuticals Holdings, Inc., Avila Therapeutics, Inc., Edimer Pharmaceuticals, Inc., Sesen Bio, Inc., Blueprint Medicines Corp., and Warp Drive Bio, Inc. She was also the President, Chief Financial Officer & Treasurer at Jounce Therapeutics, Inc. and the Chief Financial Officer & Treasurer at Voyager Therapeutics, Inc. Prior to that, she was the Chief Financial Officer & Owner at Kcd Financial Consultants LLC.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMUGENE LTD
0,00% | 12/01/2024 | 119 048 ( 0,00% ) | 5 305 $ | 31/05/2024 |
-.--% | 21/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
KINETA, INC.
-.--% | 25/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
| 08/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Kimberlee Drapkin
| Sociétés | Poste | Début |
|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/04/2022 |
| IMUGENE LIMITED | Directeur/Membre du Conseil | 21/06/2023 |
| KINETA, INC. | Directeur/Membre du Conseil | 01/07/2023 |
Anciens postes connus de Kimberlee Drapkin
| Sociétés | Poste | Fin |
|---|---|---|
| LENZ THERAPEUTICS, INC. | Directeur Général | 01/03/2024 |
| JOUNCE THERAPEUTICS, INC. | President | 03/05/2023 |
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | 01/12/2022 |
| YUMANITY THERAPEUTICS | Directeur/Membre du Conseil | 01/12/2022 |
| PROTEOSTASIS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2020 |
Formation de Kimberlee Drapkin
| Babson College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| IMUGENE LIMITED | Health Technology |
| KINETA, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Predix Pharmaceuticals, Inc.
 Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Health Technology |
Predix Pharmaceuticals Holdings, Inc.
 Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Health Technology |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
NinePoint Medical, Inc.
 NinePoint Medical, Inc. Medical SpecialtiesHealth Technology NinePoint Medical, Inc. develops and manufactures medical devices. It designs, manufactures, and sells an Optical Coherence Tomography (OCT) imaging platform for clinical use in gastroenterology, pulmonology, urology, gynecology, evaluation of human tissue microstructure. The company is headquartered in Bedford, MA. | Health Technology |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Health Technology |
Yumanity Therapeutics, Inc.
 Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
